Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation

被引:77
作者
Berndt, Ernst [1 ]
Aitken, Murray [2 ]
机构
[1] MIT, Sloan Sch Management, 100 Main St,E62-518, Cambridge, MA 02142 USA
[2] IMS Inst Healthcare Informat, 11 Waterview Blvd, Parsippany, NJ 07054 USA
关键词
Pharmaceuticals; Waxman-Hatch Legislation; Price Competition; Brand Drugs; Generic Drugs; Branded Generic Drugs;
D O I
10.1080/13571516.2011.584423
中图分类号
F [经济];
学科分类号
02 ;
摘要
We examine market share and price trends in the quarter century since the 1984 Waxman-Hatch legislation. The generic share of US retail prescriptions has grown from 18.6% in 1984 to 74.5% in 2009, with a notable acceleration in recent years. Whereas in 1994 the generic price index fell from 100 to 65 in the 24 months following initial generic entry, in 2009 the comparable price index was 28. For the prescription drugs most commonly used by beneficiaries in Medicare Part D, rather than increasing by 25-28% as has been reported by the American Association of Retired Persons (focusing entirely on brand prices), we find that once one incorporates substitution to lower priced generics following patent expiration, average price per prescription fell by 21.3% from 2006-09. Finally, we find that the weighted mean reduction in pharmaceutical daily treatment cost across nine therapeutic areas equaled 35.1% at 24 months post-generic entry.
引用
收藏
页码:177 / 201
页数:25
相关论文
共 23 条
  • [1] Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point
    Aitken, Murray
    Berndt, Ernst R.
    Cutler, David M.
    [J]. HEALTH AFFAIRS, 2009, 28 (01) : W151 - W160
  • [2] Berndt ER, 2000, HANDB ECON, V17, P119
  • [3] The US pharmaceutical industry: Why major growth in times of cost containment?
    Berndt, ER
    [J]. HEALTH AFFAIRS, 2001, 20 (02) : 100 - 114
  • [4] MarketWatch - Authorized generic drugs, price competition, and consumers' welfare
    Berndt, Ernst R.
    Mortimer, Richard
    Bhattacharjya, Ashoke
    Parece, Andrew
    Tuttle, Edward
    [J]. HEALTH AFFAIRS, 2007, 26 (03) : 790 - 799
  • [5] Berndt ErnstR., 2010, 16297 NAT BUR EC RES
  • [6] Cook A, 1998, INCREASED COMPETITIO
  • [7] Are there potential problems with generic substitution of antiepileptic drugs? A review of issues
    Crawford, P
    Feely, M
    Guberman, A
    Kramer, G
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2006, 15 (03): : 165 - 176
  • [8] Dinan Stephen, 2010, WASHINGTON TIMES
  • [9] Dong-Churl Suh, 1998, J RES PHARM EC, V9, P17
  • [10] Federal Trade Commission, 2009, AUTH GEN INT REP FED